摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6'-methoxy-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline] | 885269-27-2

中文名称
——
中文别名
——
英文名称
6'-methoxy-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]
英文别名
6-methoxyspiro[2,3-dihydro-1H-isoquinoline-4,1'-cyclopropane]
6'-methoxy-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]化学式
CAS
885269-27-2
化学式
C12H15NO
mdl
MFCD08234534
分子量
189.257
InChiKey
YZRYNJIQEPUEAY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    321.3±42.0 °C(Predicted)
  • 密度:
    1.14±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    21.3
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] CYP11A1 INHIBITORS<br/>[FR] INHIBITEURS DE CYP11A1
    申请人:ORION CORP
    公开号:WO2021229152A1
    公开(公告)日:2021-11-18
    The present invention relates to a compound of formula (I) or (II) wherein R1, R2, R3, R4, R5, R23, R24, R25, R26, R27, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) or (II) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    本发明涉及一种具有式(I)或(II)的化合物,其中R1、R2、R3、R4、R5、R23、R24、R25、R26、R27、L、A和B如权利要求书中所定义,或其药学上可接受的盐。式(I)或(II)的化合物具有作为细胞色素P450单加氧酶11A1(CYP11A1)抑制剂的效用。这些化合物在治疗类固醇受体,特别是雄激素受体依赖性疾病和症状,如前列腺癌中作为药物是有用的。
  • [EN] 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1<br/>[FR] 2-AMINOQUINAZOLINE 7-PHÉNYL SUBSTITUÉE, INHIBITEURS DE HPK1
    申请人:MERCK SHARP & DOHME
    公开号:WO2022098806A1
    公开(公告)日:2022-05-12
    Compounds of the following formula (I); or the pharmaceutically acceptable salts thereof, are inhibitors of haematopoietic progenitor kinase 1 (HPK1) useful in the treatment of diseases or disorders associated with HPK1. Also disclosed herein are uses of these compounds in the potential treatment or prevention of an HPK1-associated disease or disorder. Also disclosed herein are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of an HPK1-associated disease or disorder.
    以下公式(I)的化合物或其药学上可接受的盐是血液祖细胞激酶1(HPK1)的抑制剂,可用于治疗与HPK1相关的疾病或紊乱。本文还披露了这些化合物在潜在的治疗或预防HPK1相关疾病或紊乱中的用途。本文还披露了包含一种或多种化合物的组合物。本文还披露了这些组合物在潜在的预防或治疗HPK1相关疾病或紊乱中的用途。
  • [EN] DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1<br/>[FR] INHIBITEURS DE DIAMINOPYRIMIDINE CARBOXAMIDE DE HPK1
    申请人:MERCK SHARP & DOHME
    公开号:WO2022098809A1
    公开(公告)日:2022-05-12
    Compounds of the formula I: or the pharmaceutically acceptable salts thereof, are inhibitors of haematopoietic progenitor kinase 1 (HPK1) useful in the treatment of diseases or disorders associated with HPK1. Also disclosed herein are uses of these compounds in the potential treatment or prevention of an HPK1-associated disease or disorder. Also disclosed herein are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of an HPK1-associated disease or disorder.
    公式I的化合物或其药学上可接受的盐是血液造血祖细胞激酶1(HPK1)的抑制剂,可用于治疗与HPK1相关的疾病或紊乱。本文还披露了这些化合物在潜在的治疗或预防HPK1相关疾病或紊乱中的用途。本文还披露了包含一个或多个化合物的组合物。此外,本文还披露了这些组合物在潜在的预防或治疗HPK1相关疾病或紊乱中的用途。
查看更多